Rising Danger of E-cigarettes in Brazil: Evali and Health Implications

Regulations by 2FIRSTS.ai
Dec.27.2023
Rising Danger of E-cigarettes in Brazil: Evali and Health Implications
The high number of smokers in Campo Grande, Brazil, has raised concerns as experts warn of a new lung disease caused by e-cigarettes.

According to recent reports from Brazilian news outlet Correiodoestado, data collected through telephone surveys (Vigitel 0) for monitoring risk and protective factors reveals a high number of smokers in the city. Among them, 6.9% are male and 8.6% are female.

 

As more and more individuals adopt the use of e-cigarettes, medical experts are issuing warnings about a newly emerging lung illness called Evali, specifically caused by the use of e-cigarettes.

 

Healthcare professionals are engaged in a battle against e-cigarettes, according to respiratory disease expert Henrique Ferreira de Brito, as these devices are deemed more harmful than conventional cigarettes.

 

Although e-cigarette devices, also known as Electronic Smoking Devices (DEF), do not burn tobacco, their nicotine content is higher than that of "regular" cigarettes, resulting in greater and faster dependency.

 

Doctors say that e-cigarettes have a higher dependency, contain higher levels of nicotine, and can reach the human brain faster, resulting in a dependency on nicotine additives. Therefore, in addition to the inherent dangers of nicotine itself, e-cigarettes also contain other substances different from traditional cigarettes that pose serious health risks.

 

The doctor further explained that these substances are associated with various diseases, including heart disease, lung disease, cardiovascular disease, cancer, and Evali.

 

The São Paulo Research Foundation (Fapesp) has published an article revealing a brief history of this new type of lung disease, which was first discovered in the United States in 2009.

 

At the time, many young people in their twenties, some of whom had never suffered from respiratory diseases before, were experiencing symptoms such as difficulty breathing, coughing, and chest pains in American hospitals. Additionally, many individuals also reported abdominal pain, nausea, vomiting, diarrhea, fatigue, fever, and weight loss.

 

According to this historical record, all patients have one common factor: they are all users of e-cigarettes. In Brazil, there have been recorded cases of Evali, some of which also exhibit typical symptoms of viral pneumonia caused by Covid-19.

 

A recent study conducted by the Brazilian Institute of Geography and Statistics (IBGE) revealed that the teenage e-cigarette usage rate in Campo Grande is the highest in Brazil, with 0.9% of ninth-grade students having already tried e-cigarettes.

 

Doctors have warned that the sale, import, distribution, and marketing of e-cigarettes are prohibited under Resolution of the Collegiate Board. Although the use itself is not banned, currently all buying and selling is prohibited. Young people are particularly susceptible to the allure of e-cigarettes and may mistakenly believe they are harmless. However, this is a lie, as e-cigarettes, even those without nicotine, pose significant health risks.

 

Doctors say that factors contributing to the difficulties of quitting smoking include the release of dopamine when nicotine is consumed. Users constantly crave that feeling, which leads to an escalation in both frequency and quantity of smoking. However, in addition to chemical dependence, there are also psychological and physiological dependencies.

 

In order to quit smoking, doctors recommend that besides the individual's determination, they should also have a medical team consisting of a nutritionist, a psychologist, and a pulmonary specialist to accompany them. These professionals will assist in changing habits and utilize medications that aid in improving the chemical dependency sensation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK police have carried out a nationwide crackdown under Operation Machinize 2, targeting illegal vapes, counterfeit goods, and grey-market businesses. Raids on more than 2,700 premises led to 924 arrests and the seizure of 111,000 illegal vapes, 70kg of cannabis, 4.5m cigarettes, and £10.7m in proceeds.
Nov.11 by 2FIRSTS.ai
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia announced that its independent non-executive director Datuk Seri Dr Mohd Nizom Sairi has been re-designated as board chairman effective January 1, 2026.
Jan.04 by 2FIRSTS.ai
Australia’s TGA Seizes Illicit Vaping Products Worth Over  US$670,000 in Bendigo
Australia’s TGA Seizes Illicit Vaping Products Worth Over US$670,000 in Bendigo
Australia’s Therapeutic Goods Administration (TGA) has seized illicit vaping products with an estimated street value exceeding A$1 million (approximately US$670,000) following an enforcement operation in Bendigo, Victoria.
Dec.24 by 2FIRSTS.ai
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco (JT) announced that Ploom AURA has added a second limited-edition colorway, “Bronze Royal,” which will be available in limited quantities through official channels starting November 11, priced at approximately $27.3.
Nov.12 by 2FIRSTS.ai
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26